Literature DB >> 15358028

Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy.

Sara L Van Driest1, Michele A Jaeger, Steve R Ommen, Melissa L Will, Bernard J Gersh, A Jamil Tajik, Michael J Ackerman.   

Abstract

OBJECTIVES: We sought to determine the prevalence and phenotype of beta-myosin heavy chain gene MYH7 mutations in a large cohort of unrelated patients with hypertrophic cardiomyopathy (HCM).
BACKGROUND: Hypertrophic cardiomyopathy is a heterogeneous cardiac disease. MYH7 mutations are one of the most common genetic causes of HCM and have been associated with severe hypertrophy, young age of diagnosis, and high risk of sudden cardiac death. However, these clinical findings from large, family studies have not been confirmed in a large unrelated cohort.
METHODS: Deoxyribonucleic (DNA) samples obtained from 389 HCM outpatients seen at this tertiary referral center were analyzed for mutations, using polymerase chain reaction, denaturing high-performance liquid chromatography, and DNA sequencing for all 38 protein-coding exons of MYH7. Clinical data were extracted from patient records blinded to patient genotype.
RESULTS: Fifty-eight patients (15%) harbored 40 different mutations in MYH7. Compared with HCM patients without MYH7 mutations, HCM patients with MYH7 were younger at diagnosis (32.9 vs. 42.7 years, p = 0.0002), had more hypertrophy (left ventricular wall thickness of 24.2 vs. 21.1 mm, p = 0.0009), and more frequently underwent myectomy (60% vs. 38%, p = 0.002). The HCM patients with MYH7 mutations more often had a family history of HCM (43% vs. 29%, p = 0.006), but there was no difference in family history of sudden death (16% vs. 14%, p = NS).
CONCLUSIONS: In this setting, HCM patients with MYH7 were diagnosed at a younger age and had more hypertrophy, but they had no greater frequency of sudden death among first-degree relatives. Although these associations may prove useful for targeted gene screening, caution should be exercised in terms of using pathogenic status in risk stratification.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15358028     DOI: 10.1016/j.jacc.2004.04.039

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  63 in total

1.  Role of insert-1 of myosin VI in modulating nucleotide affinity.

Authors:  Olena Pylypenko; Lin Song; Gaelle Squires; Xiaoyan Liu; Alan B Zong; Anne Houdusse; H Lee Sweeney
Journal:  J Biol Chem       Date:  2011-01-29       Impact factor: 5.157

2.  Fluorescence spectra of cardiac myosin and in vivo experiment: studies on daunorubicin-induced cardiotoxicity.

Authors:  Yang Liu; Chi Chen; Xiaoxiang Duan; Wenting Ma; Man Wang; Mengyi Tu; Ying Chen
Journal:  Iran J Basic Med Sci       Date:  2015-12       Impact factor: 2.699

3.  LAMP2 microdeletions in patients with Danon disease.

Authors:  Zhao Yang; Birgit H Funke; Linda H Cripe; G Wesley Vick; Debora Mancini-Dinardo; Liana S Peña; Ronald J Kanter; Brenda Wong; Brandy H Westerfield; Jaquelin J Varela; Yuxin Fan; Jeffrey A Towbin; Matteo Vatta
Journal:  Circ Cardiovasc Genet       Date:  2010-02-20

4.  Estimate of the abundance of cardiomyopathic mutations in the β-myosin gene.

Authors:  Micah Hamady; Massimo Buvoli; Leslie A Leinwand; Rob Knight
Journal:  Int J Cardiol       Date:  2009-01-26       Impact factor: 4.164

5.  The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study.

Authors:  Martin Penicka; Pavel Gregor; Roman Kerekes; Dan Marek; Karol Curila; Jiri Krupicka
Journal:  J Mol Diagn       Date:  2008-12-12       Impact factor: 5.568

6.  Cardiomyopathy mutations in the tail of β-cardiac myosin modify the coiled-coil structure and affect integration into thick filaments in muscle sarcomeres in adult cardiomyocytes.

Authors:  Marcin Wolny; Melanie Colegrave; Lucy Colman; Ed White; Peter J Knight; Michelle Peckham
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

7.  Genotype phenotype correlations of cardiac beta-myosin heavy chain mutations in Indian patients with hypertrophic and dilated cardiomyopathy.

Authors:  Taranjit Singh Rai; Shamim Ahmad; Ajay Bahl; Monica Ahuja; Tarunveer Singh Ahluwalia; Balvinder Singh; K K Talwar; Madhu Khullar
Journal:  Mol Cell Biochem       Date:  2008-10-25       Impact factor: 3.396

8.  Formin homology 2 domain containing 3 variants associated with hypertrophic cardiomyopathy.

Authors:  Eric C Wooten; Virginia B Hebl; Matthew J Wolf; Sarah R Greytak; Nicole M Orr; Isabelle Draper; Jenna E Calvino; Navin K Kapur; Martin S Maron; Iftikhar J Kullo; Steve R Ommen; J Martijn Bos; Michael J Ackerman; Gordon S Huggins
Journal:  Circ Cardiovasc Genet       Date:  2012-12-19

9.  Hypertrophic cardiomyopathy family with double-heterozygous mutations; does disease severity suggest doubleheterozygosity?

Authors:  I A W van Rijsingen; J F Hermans-van Ast; Y H J M Arens; S M Schalla; C E M de Die-Smulders; A van den Wijngaard; Y M Pinto
Journal:  Neth Heart J       Date:  2009-12       Impact factor: 2.380

Review 10.  Genetic determinants of cardiac hypertrophy.

Authors:  Ali J Marian
Journal:  Curr Opin Cardiol       Date:  2008-05       Impact factor: 2.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.